Results of Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 2024
Mumbai: Philogen S.p.A. and Sun Pharmaceutical Industries Limited have announced that the primary results of the Nidlegy Phase III PIVOTAL trial (NCT02938299) will be the object of an oral presentation at ASCO by Prof. Dr. Axel Hauschild (Abstract #LBA9501 …